低分子肝素预防晚期肿瘤长期卧床患者深静脉血栓形成的疗效评价.docVIP

低分子肝素预防晚期肿瘤长期卧床患者深静脉血栓形成的疗效评价 　　[摘要] 目的 分析低分子肝素预防晚期肿瘤长期卧床患者深静脉血栓形成疗效。 方法 该研究随机选取2013年5月―2015年5月该院诊治的80例晚期肿瘤长期卧床患者为对象，所有患者化验栓溶二聚体及纤维蛋白原降解产物升高。随机分组。其中，常规组不用低分子肝素，而低分子肝素组患者给予10 000 U低分子肝素皮下注射，2次/d，一共治疗两周。对比分析两组患者下肢深静脉血栓发生率差异，并对比两组不良反应。 结果 采用χ2检验分析进行数据统计，常规组患者下肢深静脉血栓发生率明显高于低分子肝素组，差异有统计学意义（P0.05）。两组均无患者出现肺栓塞。 结论 低分子肝素预防晚期肿瘤长期卧床患者深静脉血栓形成疗效非常显著，其有利于显著降低下肢深静脉血栓发生率，且安全性高，不良反应轻微，值得推广。 中国论文网 /6/view-7165142.htm 　　[关键词] 低分子肝素；晚期肿瘤长期卧床患者；深静脉血栓；疗效评价 　　[中图分类号] R5 [文献标识码] A [文章编号] 1674-0742（2015）09（c）-0068-02 　　[Abstract] Objective To analyze the efficacy of low molecular weight heparin on prevention of deep venous thrombosis of bedridden patients with advanced tumor. Methods 80 bedridden patients with advanced tumor between May 2013 and May 2015 were enrolled in this study. D-dimer and fibrinogen degradation product of the patients were tested and increased. The patients were randomized into the routine group that was not given low molecular weight heparin and the low molecular weight heparin group that was given 100，000U low molecular weight heparin by subcutaneous injection， twice a day for two weeks. The difference in incidence of deep venous thrombosis of the two groups was analyzed and the adverse reactions of the two groups were compared. Results Data statistics were analyzed using Chi-squared test. The incidence of lower extremity deep venous thrombosis of the routine group was significantly higher than that of low molecular weight heparin group and the difference had statistical significance （P0.05）. No pulmonary embolism was noted in the two groups. Conclusion The efficacy of low molecular weight heparin on prevention of deep venous thrombosis of bedridden patients with advanced tumor is remarkable. It is beneficial to reducing the incidence of lower extremity deep venous thrombosis with high safety and mild adverse reaction， which is worth popularizing. 　　[Key words] Low molecular weight heparin； Bedridden patients with advanced tumor； Deep venous thrombosis； Efficac